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Abstract
OBJECTIVE: To explore the inhibitory effect of Zish-
enshengxue capsule (ZSC) on myelosuppression in
mice induced by cyclophosphamide.
METHODS: Kunming mice were randomly as-
signed into a control group, myelosuppression
group, or groups for mice with myelosuppression
receiving high dose ZSC, middle dose ZSC, low
dose ZSC or Yixuesheng. Myelosuppression was in-
duced by peritoneal injection of cyclophospha-
mide. ZSC and cyclophosphamide were adminis-
tered simultaneously. The numbers of peripheral
blood cells and bone marrow karyocytes were
counted. Cell proliferation activity and colony for-
mation of granulocyte-monocyte series hemopoiet-
ic progenitor cells (C-GMs) and cell cycle were de-
tected.
RESULTS: The numbers of white blood cells in the
middle and high dose ZSC groups were significant-
ly increased at the 12th and 13th day (P<0.01) and
bone marrow karyocytes and cell proliferation ac-
tivity increased in the high dose ZSC group (P<
0.01) compared with the myelosuppression group.
C-GMs of middle and high dose ZSC groups signifi-
cantly increased (P<0.01). The percentage of G1
phase in the high dose ZSC group decreased (P<
0.01) and the percentage of S and G2 phase in-
creased (P<0.01).
CONCLUSION: ZSC increased the numbers of pe-
ripheral white blood cells, bone marrow karyocytes
and C-GMs. ZSC also increased cell proliferation ac-
tivity and removed the G1 phase block. Thus, ZSC
could reduce myelosuppression in mice induced by
cyclophosphamide.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
For cancer patients, chemotherapy is the optimal thera-
py available. However, chemotherapy causes myelosup-
pression that hampers the beneficial effects of the treat-
ment and decreases the clinical effect.1 Therefore, the
development of methods that relieve myelosuppression
and promote the recovery of hematogenesis to increase
the peripheral white blood cells is a key problem to the
successful completion of chemotherapy and clinical ef-
fects. Zishenshengxue capsule (ZSC) is a Chinese herb-
al compound that can treat bone marrow depression in-
duced by numerous factors especially chemotherapy
and has valid clinical effect.2 In this study, we investi-
gated the inhibitory effects of ZSC on myelosuppres-
sion in mice induced by cyclophosphamide and sug-
gest a mechanism of action.
233
JTCM |www. journaltcm. com April 15, 2013 |volume 33 | Issue 2 |
LiW et al. / Experimental Study
MATERIALS ANDMETHODS
Drugs and reagents
ZSC was provided by the Harbin Institute of Hematol-
ogy and Tumor. Granulocyte and monocyte colony
stimulating factor (GM-CSF) was purchased from
Stem Cell Technologies (Vancouver, Canada). Cyclo-
phosphamide (CTX) was purchased from Hua Lian
Company (ShangHai, China). Yixuesheng (YXS, posi-
tive control), (positive control) was purchased from
AoDong Company (JiLin, China). RPMI-1640 cell
culture medium was purchased from Gibco (Carlsbad,
CA, USA).
Animals
Kunming mice [male, (20±2) g] were provided by the
Experimental Animal Center of Harbin Medical Uni-
versity (certificate serial number 09-2-1). This research
was approved by the animal ethics committees of De-
partment of Pharmacy, Harbin Commercial University.
Preparation of mice skeletal muscle conditioned
medium
Normal Kunming mice were euthanized by cervical ver-
tebra dislocationandthenplacedin75%ethanol for 5 min
twice. The back muscles and both lower extremities
muscles were dissected and cut into 0.3 cm3 pieces,
rinsed with RPMI-1640 media and then incubated for
2 h. One g muscle was placed in 9 mL media contain-
ing 2 mL horse serum (HS) and 7 mL RPMI-1640.
The muscles were then cultured at 37°C in 5% CO2
for 7 days. The supernatant was collected and centri-
fuged for 5 min at 4°C at 500 ×g and stored at −20°C
after filtration until used.3
Detection of peripheral blood cells
Mice (n=84) were randomly assigned into 6 groups ac-
cording to weight, 14 per group as follows: control
group (control), the model myelosuppression group
(model), high dose ZSC (6.6 g/kg per day) group (H),
middle dose ZSC (3.3 g/kg per day) group (M), low
dose ZSC (1.65 g/kg per day) group (L) and YXS
(0.375 g/kg per day) group (a positive control). The
mice in the control group were given saline by peritone-
al injection and myelosuppression was induced in the
other groups by peritoneal injection of CTX (50 mg/
kg) on the 1st and 3rd day. The H, M, L and YXS
group were simultaneously administered either ZSC or
YXS by intragastric administration for 12 days. The
mice in the control and model group were adminis-
tered saline by intragastric administration (0.2 mL per
day). Peripheral blood obtained from the tails of each
group was used to measure leukocyte, erythrocyte and
platelet numbers on days 4, 5, 6, 8, 12 and 13.
Counting of bone marrow karyocytes
Another 60 mice were manipulated as above. On day
13, mice were euthanized by cervical vertebra disloca-
tion and then placed in 75% ethanol for 5 min twice.
Double femurs were removed under aseptic conditions
and bone marrow cells were flushed using 1640 medi-
um to form a single cell suspension. The suspension
was placed into a tube containing lymphocyte separa-
tion medium, and centrifuged for 5 min at 2000 × g.
The bone marrow karyocytes were removed and rinsed
twice with 1 mL sterile phosphate-buffered saline
(PBS) for 5 min at 1000 ×g then resuspended in RPMI
1640 and counted by inverted microscope.4
Cell viability analysis
The bone marrow karyocytes (2.5×105/mL) were resus-
pended in RPMI-1640 medium containing 20% HS
and 10% mouse skeletal muscle conditioned medium.
These cells were placed into 96-well plates in triplicate
and incubated at 37°C, in a 5%CO2 incubator for 48 h.
3,[4,5-dimethylthiazol-2-yl] -2,5-diphenyl-tetrazolium
bromide (MTT, 5 mg/mL)5 was then added to each
well. Then cells were incubated for another 4 h. The su-
pernatants were discarded and 180 µL DMSO was add-
ed to each well and oscillated for 10 min. The optical
density (OD) was measured at 570 nm.
Colony formation of granulocyte-monocyte series
hemopoietic progenitor cells (C-GMs)
Cells (5×104) were plated in triplicate cultures in 1 mL
of methylcellulose assay medium containing HS
(0.2 mL) and GM-CSF (100 ng/mL). The cells were
cultured at 37°C, in a 5% CO2 incubator for 7 days.
Colonies of 40 or more cells were counted as colonies,
using a inverted-phase microscope. 6
Cell cycle
A single cell suspension was collected into a centrifuge
tube and rinsed twice with cold PBS, centrifuged and
then 2 mL 70% cold ethanol was added to fix the cells
overnight at 4°C. Cells were then incubated with prop-
idium iodide (PI) in the dark for 30 min. Cells from
all groups were measured by flow cytometry (FANCS-
Canto Ⅱ, BD company, New Jersey, USA). 7
Statistical analysis
The data were expressed as mean ± standard deviation.
Statistical analysis was performed by one-way analysis
of variance. All analyses were performed with SPSS
13.0 statistical software (SPSS Inc. Chicago, IL, USA)
and P<0.05 was considered statistically significant.
RESULTS
Effect of ZSC on peripheral blood cells
As shown in Figure 1, the number of leukocytes in the
model group significantly decreased compared with the
control group (P<0.01) at days 4, 5 and 6. However,
compensation mechanisms caused an increase in the
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number of leukocytes in the model group by day 10.
On days 12 and 13 the leukocyte numbers in the H,
M, L and YXS groups were significantly increased (P<
0.01) compared with the model group. The number of
erythrocytes in the model group did not change com-
pared to the control group and administration of ZSC
or YXS had no effect on erythrocyte numbers or plate-
lets (Supplementary file).
Effect of ZSC on bone marrow karyocytes
Bone marrow karyocytes mainly include immature
cells in bone marrow such as total leukocytes, mega-
karyocytes and immature erythrocytes. As shown in
Figure 2, numbers of karyocytes in the model group
significantly decreased compared with the control
group (P<0.01). The high dose of ZSC significantly
increased karyocyte numbers compared with the mod-
el group (P<0.05) and its effect was superior to YXS.
Effects of ZSC on bone marrow cell proliferation
As shown in Figure 3, there was significant reduction
in bone marrow cell proliferation as measured by OD
in the model group compared with the control group
(P<0.01). The bone marrow cell proliferation signifi-
cantly increased after the administration of high dose
of ZSC and YXS compared with the model group (P<
0.05). As shown in Figure 4, the C-GMs numbers in
the model group significantly decreased compared with
the control group (P<0.01). Compared with the model
group, C-GMs numbers in L, M, H and YXS groups
significantly increased (P<0.05).
Effect of ZSC on cell cycle
The ratio of G1 phase in the model group increased
and the ratio of S and G2 phase decreased after CTX
administration (Figure 5). These changes in cell cycle
phase were significant compared with the control
group (P<0.05). The percentage of G1 phase cells in H
and YXS groups significantly decreased (P<0.01) and S
phase cells significantly increased (P<0.01) compared
with the model group.
DISCUSSION
Chemotherapy restricts the effect of tumor treatment
by causing myelosuppression and is an important prob-
lem that must be solved to optimize chemotherapy for
the treatment of cancer patients. Clinical studies dem-
onstrated that Batiolum and Leucogen have little effect
on myelosuppression. Although many cytokines can
stimulate cell differentiation and proliferation as well
as promote the recovery of hemogram and elevate clini-
cal effects, some side effects may occur because of the
large dosage required. Autologous bone marrow trans-
plantation does not satisfy clinical need due to its ex-
pensive cost and non-repetitive application. Therefore,
it is challenging to identify drugs from Traditional Chi-
nese Medicine or Western Medicine that have high
therapeutic efficacy with low toxicity and side effects
and that are relatively cheap.
In this study, we used CTX peritoneal injection to in-
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Figure 1 Effect of ZSC on peripheral leukocyte
Control: control group; model: the model myelosuppression group; H: high dose ZSC group; M: middle dose ZSC group; L: low
dose ZSC group; YXS: YXS group. ZSC: Zishenshengxue capsule; YXS: Yixuesheng. Data are expressed as the mean±SD (n=14 rats/


















Figure 2 Effect of ZSC on bone marrow karyocyte
Control: control group; model: the model myelosuppression
group; H: high dose ZSC group; M: middle dose ZSC group;
L: low dose ZSC group; YXS: YXS group. ZSC: Zishenshengx-
ue capsule; YXS: Yixuesheng. Data are expressed as the
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duce a mouse model of bone marrow depression and
studied the effect of ZSC administration on myelosup-
pression. After CTX injection, these mice showed a
weak mental state and retarded action with fur that
was dull, withered and disordered. In addition, the
number of leukocytes decreased after CTX injection.
However, the number of leukocytes increased compen-
satively by day 10. This may be due to a positive feed-
back loop, where the killing of blood cells in the multi-
plicative pool by CTX induced the proliferation of he-
mopoietic stem cells in the non-multiplicative pool.
Thus, large numbers of leukocytes may mature syn-
chronically and enter the blood stream, thus reducing
the number of bone marrow leukocytes. The number
of bone marrow karyocytes and proliferation activity al-
so significantly decreased. These characteristics are simi-
lar to the symptoms of cancer patients treated with che-
motherapy. Therefore, this model may simulate the my-
elosuppression state of tumor patients after chemother-
apy and may be useful for the study of the preventive
and therapeutic effects of ZSC.
Hematocytopenia describes major bone marrow depres-
sion and hypoleukemia is more notable because of its
short half-life of approximately 6-8 h. However, the
half-life of platelets and erythrocytes are relatively lon-
ger, so obvious changes are not usually observed. Leu-
kocytes increased significantly in mice on days 12 and
13 after administration of low, middle and high doses
of ZSC, and the effect of high dose ZSC was most sig-
nificant. Concurrently, bone marrow karyocytes nearly
recovered to normal levels, which reflects the prolifera-
tion state of the bone marrow cells. The bone marrow
cell viability and C-GMs increased significantly in the
ZSC groups' indicating that the number of living cells
and internal proliferation activity increased.
Cells in G1 phase increased notably after CTX induc-
tion and proliferation and differentiation were inhibit-
ed. Therefore, the later G1 phase is a key point for the
promotion of the cell cycle and also a target for drugs
and other factors that affect the cell cycle.8 How to in-
crease the number of hematopoietic cells that pass the
G1 phase checkpoint and enter S phase to recover im-
paired hematogenesis function of bone marrow by che-
motherapy is an important problem in drug studies. 9
High dose ZSC decreased the ratio of G1 phase cells
and elevated the percentage of cells in S and G2 phase.
Thus, ZSC could promote cells to pass the G1/S phase
checkpoint and successfully enter the cell cycle to facili-
tate the repair of damaged DNA and accelerate cell pro-
liferation. Therefore, ZSC treatment antagonized the
toxicity and side effects of CTX on bone marrow cells.
In summary, ZSC could reduce bone marrow lesions
caused by chemotherapy and reduce CTX-induced my-
elosuppression in mice. Furthermore, ZSC was superi-
or to YXS, a commonly used drug, at increasing the
number of bone marrow karyocytes.
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